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Clinical PerspectiveWhat Is New?Mildly elevated mean pulmonary artery pressure ≈19 to 24 mm Hg, which is below the traditional threshold of \>25 mm Hg used to define pulmonary hypertension (PH), is associated with an increased risk of all‐cause mortality.The association between mildly elevated mean pulmonary artery pressure and increased mortality is consistent when PA pressure is measured by right heart catheterization or estimated by echocardiography.What Are the Clinical Implications?Our data support efforts to update the current definition of PH and affirm the reproducibility of mean pulmonary artery pressure \>19 mm Hg as an appropriate and clinically accessible level distinguishing patients with PH from patients without PH.Acknowledging this would identify previously undiagnosed patients with PH and provide a framework in clinical practice by which to initiate careful monitoring and efforts to modify risk factors and improve outcomes.

Introduction {#jah33503-sec-0008}
============

There are accumulating data suggesting that the spectrum of clinical risk related to mean pulmonary artery pressure (mPAP) is wider than described originally.[1](#jah33503-bib-0001){ref-type="ref"} Findings from 2 large right heart catheterization (RHC) registries[2](#jah33503-bib-0002){ref-type="ref"}, [3](#jah33503-bib-0003){ref-type="ref"} and numerous other smaller clinical studies[4](#jah33503-bib-0004){ref-type="ref"}, [5](#jah33503-bib-0005){ref-type="ref"} have demonstrated that mPAP of \>19 mm Hg (previously termed "borderline pulmonary hypertension \[PH\]") is an independent risk factor for increased mortality. This observation indicates that the traditional mPAP threshold for defining PH of ≥25 mm Hg may be insufficient. This, in turn, has important potential implications for diagnosing and prognosticating patients with PH. Yet, the acceptance of a lower threshold of mPAP to identify patient populations at risk remains controversial, and formal assessment of published literature to determine a more precise estimate of risk across patient populations is lacking. Furthermore, the clinical relevance of mildly elevated PA pressure, measured by echocardiography, remains unclear.[6](#jah33503-bib-0006){ref-type="ref"} Hence, the primary objective of this study was to perform a systematic review and meta‐analysis of RHC and echocardiography studies to determine the association between mildly elevated PA pressures and mortality.

Methods {#jah33503-sec-0009}
=======

Data Sources {#jah33503-sec-0010}
------------

We searched PubMed (MEDLINE), CINHAL, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials from inception through January 31, 2018, for English‐language, peer‐reviewed publications. The following keywords and Medical Subject Heading terms were used: "hypertension, pulmonary (Medical Subject Heading)," "pulmonary artery hypertension," "pulmonary arterial hypertension," "pulmonary artery pressure," "pulmonary arterial pressure," "pulmonary artery systolic pressure," "right ventricular systolic pressure," "mPAP," "mortality (Medical Subject Heading)," and "death (Medical Subject Heading)." Reference lists of systematic reviews, meta‐analyses, and original studies identified by the electronic search were reviewed to find other potentially eligible studies. The authors declare that all supporting data are available within the article and references.

Study Selection {#jah33503-sec-0011}
---------------

Studies were included in the meta‐analysis if they: (1) included a clearly defined or identifiable study group with mildly elevated PA pressure and (2) provided the number of events and/or risk estimates for mortality in the mild PH versus referent group. We followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) and Meta‐Analysis of Observational Studies in Epidemiology (MOOSE) checklists for the protocol of our meta‐analysis.[7](#jah33503-bib-0007){ref-type="ref"}, [8](#jah33503-bib-0008){ref-type="ref"}

Data Extraction and Quality Assessment {#jah33503-sec-0012}
--------------------------------------

Three physician reviewers (D.K., S.L., and G.C.) evaluated independently study eligibility and quality, and performed data extraction using standardized data collection sheets. Disagreements were resolved by consensus. Study quality was evaluated using the Newcastle‐Ottawa Scale, which assigns a star for 3 areas of study quality: selection (4 criteria), comparability (1 criterion), and outcome (3 criteria).[9](#jah33503-bib-0009){ref-type="ref"} A study can be awarded a maximum of 1 star for each numbered criterion within the selection and outcome categories. A maximum of 2 stars can be given for comparability (Table [1](#jah33503-tbl-0001){ref-type="table"}).

###### 

Assessment of the Quality of Nonrandomized Studies Included in the Meta‐Analysis Using the Newcastle‐Ottawa Scale

  Study                                                            Selection   Comparability   Outcome
  ---------------------------------------------------------------- ----------- --------------- ---------
  Valerio et al, 2013[10](#jah33503-bib-0010){ref-type="ref"}      ✩★★★        ✩✩              ★★★
  Heresi et al, 2013[11](#jah33503-bib-0011){ref-type="ref"}       ★★★★        ★★              ★★★
  Kovacs et al, 2014[5](#jah33503-bib-0005){ref-type="ref"}        ★★★★        ✩✩              ★★★
  Suzuki et al, 2014[12](#jah33503-bib-0012){ref-type="ref"}       ✩★★★        ★★              ★★★
  Maron et al, 2016[3](#jah33503-bib-0003){ref-type="ref"}         ✩★★★        ★★              ★★★
  Takahashi et al, 2016[13](#jah33503-bib-0013){ref-type="ref"}    ✩★★★        ★★              ★★★
  Douschan et al, 2018[4](#jah33503-bib-0004){ref-type="ref"}      ★★★★        ✩✩              ★★★
  Assad et al, 2017[2](#jah33503-bib-0002){ref-type="ref"}         ★★★★        ★★              ★★★
  Abramson et al, 1992[14](#jah33503-bib-0014){ref-type="ref"}     ✩★★★        ✩✩              ★★★
  Kjaergaard et al, 2007[15](#jah33503-bib-0015){ref-type="ref"}   ✩★★★        ✩✩              ★★★
  Shalaby et al, 2008[16](#jah33503-bib-0016){ref-type="ref"}      ☆★★★        ★★              ★★★
  Lam et al, 2009[17](#jah33503-bib-0017){ref-type="ref"}          ★★★★        ✩✩              ★★★
  Damy et al, 2010[18](#jah33503-bib-0018){ref-type="ref"}         ✩★★★        ✩✩              ★★★
  Cabrita et al, 2013[19](#jah33503-bib-0019){ref-type="ref"}      ✩★★★        ★★              ★★★
  Choudhary et al, 2014[20](#jah33503-bib-0020){ref-type="ref"}    ✩★★★        ★★              ★★★

Study quality was\\xA0evaluated using the Newcastle‐Ottawa Scale, which assigns a\\xA0star for 3 areas of study quality: selection (4 criteria),\\xA0comparability (1 criterion), and outcome (3 criteria). A study\\xA0can be awarded a maximum of 1 star for each numbered\\xA0criterion within the selection and outcome categories. A\\xA0maximum of 2 stars can be given for comparability. ![](JAH3-7-e009729-g009.jpg "image") = criterion not satisfied (star not awarded) ![](JAH3-7-e009729-g010.jpg "image") = criterion satisfied (star awarded)

Exposure {#jah33503-sec-0013}
--------

The exposure was mild PH. Mild PH was defined as a lower limit mPAP of 19 to 21.5 mm Hg and an upper limit mPAP of ≈25 mm Hg, except some studies in which few patients (n=11 patients) with mPAP \>25 mm Hg were also included in the mild PH group because of unavailability of mortality data separately for these patients (Table [2](#jah33503-tbl-0002){ref-type="table"}). For echocardiography studies that reported only the tricuspid regurgitation velocity or gradient (n=3), pulmonary artery systolic pressure (PASP) was calculated as tricuspid regurgitation gradient plus an assumed right atrial pressure of 5 mm Hg. This approach has been used in prior studies.[17](#jah33503-bib-0017){ref-type="ref"}, [20](#jah33503-bib-0020){ref-type="ref"}, [21](#jah33503-bib-0021){ref-type="ref"}, [22](#jah33503-bib-0022){ref-type="ref"} mPAP was calculated using the following formula: (0.61×PASP) + 2 mm Hg.[23](#jah33503-bib-0023){ref-type="ref"}

###### 

Characteristics of Studies Included in the Meta‐Analysis

  Study                                                            Study Design                Data Source                                               Study Population                                                                                       N[a](#jah33503-note-0002){ref-type="fn"}   RHC or Echocardiographic Index   Study Groups                                                                                                    Follow‐Up Duration, y                       
  ---------------------------------------------------------------- --------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------ -------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------------- ------
  Valerio et al, 2013[10](#jah33503-bib-0010){ref-type="ref"}      Retrospective               The Royal Free Hospital Pulmonary Hypertension Database   Systemic sclerosis                                                                                     199                                        RHC mPAP                         mPAP 21--24 mm Hg                                                                                               mPAP ≤20 mm Hg                              5 
  Heresi et al, 2013[11](#jah33503-bib-0011){ref-type="ref"}       Retrospective               Cleveland Clinic Pulmonary Hypertension Registry          Cardiac disease (16.2%), pulmonary disease (29.7%), CTD (18.9%), other (6.1%)                          82                                         RHC mPAP                         mPAP 21--24 mm Hg                                                                                               mPAP ≤20 mm Hg                              5 
  Kovacs et al, 2014[5](#jah33503-bib-0005){ref-type="ref"}        Retrospective               Single center                                             Cardiac disease (23%), pulmonary disease (23%), CTD (43%)                                              141                                        RHC mPAP                         mPAP 21--24 mm Hg                                                                                               mPAP \<21 mm Hg                             4.2 
  Suzuki et al, 2014[12](#jah33503-bib-0012){ref-type="ref"}       Retrospective               Single center                                             LD‐CTD                                                                                                 100                                        RHC mPAP                         mPAP ≥20 mm Hg[b](#jah33503-note-0003){ref-type="fn"}                                                           mPAP \<20 mm Hg                             5 
  Maron et al, 2016[3](#jah33503-bib-0003){ref-type="ref"}         Retrospective               VA‐CART                                                   US Veterans (HF \[38.7%\], pulmonary disease \[27.8%\], CTD \[4.6%\])                                  9237                                       RHC mPAP                         mPAP 19--24 mm Hg                                                                                               mPAP ≤18 mm Hg                              5 
  Takahashi et al, 2016[13](#jah33503-bib-0013){ref-type="ref"}    Retrospective               Single center                                             CTD‐ILD                                                                                                68                                         RHC mPAP                         mPAP ≥20 mm Hg[c](#jah33503-note-0004){ref-type="fn"}                                                           mPAP \<20 mm Hg                             7 
  Douschan et al, 2018[4](#jah33503-bib-0004){ref-type="ref"}      Retrospective+prospective   Single center                                             Patients with cardiopulmonary disease with unexplained dyspnea and/or at risk of PH referred for RHC   257                                        RHC mPAP                         mPAP 20.6--24.9 mm Hg                                                                                           mPAP \<20.6 mm Hg                           5 
  Assad et al, 2017[2](#jah33503-bib-0002){ref-type="ref"}         Retrospective               Single center                                             Patients referred for RHC (HF \[32.1%\], pulmonary disease \[14.3%\], CTD \[2.0%\])                    1659                                       RHC mPAP                         mPAP 19--24 mm Hg                                                                                               mPAP ≤18 mm Hg                              5 
  Abramson et al, 1992[14](#jah33503-bib-0014){ref-type="ref"}     Retrospective               Single center                                             Ischemic or idiopathic dilated cardiomyopathy                                                          87                                         Echocardiographic TRV            TRV 2.6--3.0 m/s (mPAP 21.5--27.0 mm Hg[d](#jah33503-note-0005){ref-type="fn"})                                 TRV ≤2.5 m/s (mPAP ≤20.3 mm Hg)             2.3 
  Kjaergaard et al, 2007[15](#jah33503-bib-0015){ref-type="ref"}   Post hoc analysis of RCT    ECHOS                                                     Heart failure                                                                                          194                                        Echocardiographic RVSP           RVSP 31--38 mm Hg (mPAP 20.9--25.2 mm Hg[d](#jah33503-note-0005){ref-type="fn"})                                RVSP \<31 (mPAP \<20.9 mm Hg)               4 
  Shalaby et al, 2008[16](#jah33503-bib-0016){ref-type="ref"}      Retrospective               Multicenter                                               CRT recipients                                                                                         176                                        Echocardiographic PASP           PASP 30--44 mm Hg (mPAP 20.3--28.8 mm Hg[d](#jah33503-note-0005){ref-type="fn"})                                PASP 20--29 mm Hg (mPAP 14.2--19.7 mm Hg)   1.6 
  Lam et al, 2009[17](#jah33503-bib-0017){ref-type="ref"}          Prospective                 Olmsted County                                            Random sample of the Olmsted County population ≥45 y                                                   1234                                       Echocardiographic PASP           PASP 30--32 mm Hg (mPAP 20--21.5 mm Hg[d](#jah33503-note-0005){ref-type="fn"})                                  PASP 15--29 mm Hg (mPAP 11.2--19.7 mm Hg)   8 
  Damy et al, 2010[18](#jah33503-bib-0018){ref-type="ref"}         Retrospective               Single center                                             Heart failure                                                                                          311                                        Echocardiographic TRG            TRG 26--35 mm Hg (mPAP 20.9--26.4 mm[d](#jah33503-note-0005){ref-type="fn"})                                    TRG ≤25 mm Hg (mPAP ≤20.3 mm Hg)            6.7 
  Cabrita et al, 2013[19](#jah33503-bib-0019){ref-type="ref"}      Retrospective               Multicenter                                               Sickle cell disease                                                                                    164                                        Echocardiographic TRV            TRV ≥2.5 m/s[e](#jah33503-note-0006){ref-type="fn"} (mPAP ≥20.3 mm Hg[d](#jah33503-note-0005){ref-type="fn"})   TRV \<2.5 m/s (mPAP \<20.3 mm Hg)           5.7 
  Choudhary et al, 2014[20](#jah33503-bib-0020){ref-type="ref"}    Retrospective               JHS                                                       Population‐based cohort of blacks residing in Jackson, MS                                              2567                                       Echocardiographic PASP           PASP 28--32 mm Hg (mPAP 19.1--21.5 mm Hg[d](#jah33503-note-0005){ref-type="fn"})                                PASP 10--27 mm Hg (mPAP 8.1--18.5 mm Hg)    3.5 

CRT indicates cardiac resynchronization therapy; CTD, connective tissue disease; CTD‐ILD, CTD‐associated interstitial lung disease; ECHOS, Echocardiography and Heart Outcome Study; HF, heart failure; JHS, Jackson Heart Study; LD‐CTD, lung‐dominant CTD; mPAP, mean pulmonary artery pressure; PASP, pulmonary artery systolic pressure; PH, pulmonary hypertension; RCT, randomized controlled trial; RHC, right heart catheterization; RVSP, right ventricular systolic pressure; TRG, tricuspid regurgitation gradient; TRV, tricuspid regurgitation velocity; VA‐CART, Veterans Affairs Clinical Assessment Reporting and Tracking.

Number of patients included in the meta‐analysis. The actual number of patients in the original studies may be different.

Includes 4 patients with mPAP \>25 mm Hg.

Includes 6 patients with mPAP \>25 mm Hg.

Calculated mPAP using the following formula: (0.61×PASP) + 2 mm Hg.

Includes 3 patients with TRV \>3.0 m/s.

Outcomes {#jah33503-sec-0014}
--------

The primary outcome of interest was all‐cause mortality.

Statistical Analysis {#jah33503-sec-0015}
--------------------

Random‐effects models of DerSimonian and Laird were used to calculate pooled risk ratio (RR) and corresponding 95% confidence interval (CI) for mortality. For studies that reported risk‐adjusted time‐to‐event estimates (adjusted hazard ratio \[HR\]) and the corresponding 95% CI, we performed secondary analyses using the generic inverse variance method to estimate pooled HR using a random‐effects model. Secondary analyses were also performed using fixed‐effect models. Heterogeneity was assessed using the Higgins I^2^ statistic, with values \<25% and \>75% considered indicative of low and high heterogeneity, respectively. Pooled estimates were calculated for all studies as well as the a priori defined subgroups of echocardiography and RHC studies. Publication bias was assessed visually by asymmetry in funnel plots and formally using Egger\'s regression test and the Begg‐Mazumdar rank correlation test. To assess the impact of publication bias on the risk estimate, we used Duval and Tweedie\'s Trim and Fill as well as cumulative meta‐analysis (after sorting the included studies from largest to smallest size).[24](#jah33503-bib-0024){ref-type="ref"}, [25](#jah33503-bib-0025){ref-type="ref"}

All tests were 2 tailed, with a *P*\<0.05 considered statistically significant. Analyses were performed using the Review Manager Version 5.3 (The Nordic Cochrane Center, The Cochrane Collaboration, 2014, Copenhagen, Denmark) and Comprehensive Meta‐Analysis Version 3.0 (Biostat, Englewood, NJ).

Results {#jah33503-sec-0016}
=======

The database search yielded 11 184 articles. After removing duplicates, 7920 articles were screened at the title/abstract level and 7880 were excluded for various reasons (eg, systematic reviews, case reports, studies that included only patients with known PH, and studies with no data on mortality). Forty full‐text articles were assessed for eligibility (Figure [1](#jah33503-fig-0001){ref-type="fig"}). Fifteen (8 RHC and 7 echocardiography) studies were included in the meta‐analysis.[2](#jah33503-bib-0002){ref-type="ref"}, [3](#jah33503-bib-0003){ref-type="ref"}, [4](#jah33503-bib-0004){ref-type="ref"}, [5](#jah33503-bib-0005){ref-type="ref"}, [10](#jah33503-bib-0010){ref-type="ref"}, [11](#jah33503-bib-0011){ref-type="ref"}, [12](#jah33503-bib-0012){ref-type="ref"}, [13](#jah33503-bib-0013){ref-type="ref"}, [14](#jah33503-bib-0014){ref-type="ref"}, [15](#jah33503-bib-0015){ref-type="ref"}, [16](#jah33503-bib-0016){ref-type="ref"}, [17](#jah33503-bib-0017){ref-type="ref"}, [18](#jah33503-bib-0018){ref-type="ref"}, [19](#jah33503-bib-0019){ref-type="ref"}, [20](#jah33503-bib-0020){ref-type="ref"} The characteristics of the included studies are shown in Table [2](#jah33503-tbl-0002){ref-type="table"}. Of the 15 studies, 12 were retrospective, 1 was prospective, 1 was ambispective, and 1 was a post hoc analysis of a randomized controlled trial. The 15 studies included 16 482 patients (7451 \[45.2%\] with mild PH \[6037 diagnosed by RHC, and 1414 diagnosed by echocardiography\] and 9031 \[56.4%\] in the referent group). The mean duration of follow‐up weighted for the sample size was 5.2 years. The studies included in the meta‐analysis encompassed a broad spectrum of the patient population at risk of PH, including those with cardiac, pulmonary, connective tissue, and hematologic diseases. Table [3](#jah33503-tbl-0003){ref-type="table"} shows the characteristics of patients in the 2 groups in the included studies. The mean/median age of patients ranged from 41 to 77 years, and the proportion of women ranged from 3.5% to 90%.

![Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) study selection flow diagram. RHC indicates right heart catheterization.](JAH3-7-e009729-g001){#jah33503-fig-0001}

###### 

Baseline Characteristics of Patients in the Included Studies

  Characteristics       Valerio et al[10](#jah33503-bib-0010){ref-type="ref"}   Heresi et al[11](#jah33503-bib-0011){ref-type="ref"}   Kovacs et al[5](#jah33503-bib-0005){ref-type="ref"}   Suzuki et al[12](#jah33503-bib-0012){ref-type="ref"}   Maron et al[3](#jah33503-bib-0003){ref-type="ref"}   Takahashi et al[13](#jah33503-bib-0013){ref-type="ref"}   Douschan et al[4](#jah33503-bib-0004){ref-type="ref"}   Assad et al[2](#jah33503-bib-0002){ref-type="ref"}                                                                                                                        
  --------------------- ------------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------- ------------------- ------------------- ---------- ----------- ------------------- ------------------- ------------- -------------
  Age, y                                                                                                                               51±17                                                 59±14                                                  57.3±12.5                                            65.8±12.5                                                 64.5±8.3                                                67.9±6.4                                             64.3 (59.6--73.0)   65.2 (60.3--73.5)   62.9±19    61.9±11.4   60 (50--69)         67 (58--75)         59 (47--68)   62 (52--71)
  Female                                                                                                                               88.2                                                  90                                                                                                                                                                    37.8                                                    27.8                                                 3.5                 3.4                 58.6       43.8        72.5                70                  46            46
  Race (nonwhite)                                                                                                                                                                                                                                                                                                                                                                                                                                                               20.9                20.7                                                                               10            15
  BMI, kg/m^2^                                                                                                                                                                                                                                      25.6±4.5                                             27.5±5.9                                                  23.5±3.8                                                24.8±4.6                                             28 (24.6--31.5)     29.6 (26--34)       22.7±3.9   23.8±4.3    26.2 (23.3--29.4)   26.7 (22.9--31.2)   27 (23--31)   29 (25--34)
  Hypertension                                                                                                                                                                                                                                                                                                                                                                                                                                                                  82.3                86                                                                                 73            82
  DM                                                                                                                                                                                                                                                                                                                                                                                                                                                                            33.4                40.6                                                                               25            37
  Smoking                                                                                                                                                                                                                                                                                                                                                          58.5                                                    72.2                                                                                         37.9       56.3        55.5                50                                
  Obesity                                                                                                                              29.4                                                  30                                                                                                                                                                                                                                                                                 33.7                47.3                                                                               29            43
  CAD                                                                                                                                                                                                                                                                                                                                                                                                                                                                           78.6                82.4                                                                               72            76
  Atrial fibrillation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  20            27
  COPD                                                                                                                                                                                                                                                                                                                                                                                                                                                                          23                  30.8                                                                               5             14
  ILD                                                                                                                                                                                                                                                                                                                                                              100                                                     100                                                  0.4                 0.7                                                                                5             6
  OSA                                                                                                                                                                                                                                                                                                                                                                                                                                                                           7.3                 10.2                                                                               5             10
  Anemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               36            44
  Heart failure                                                                                                                                                                                                                                                                                                                                                                                                                                                                 34.1                42.7                                                                               25            39
  CTD                                                                                                                                                                                                                                                                                                                                                              100                                                     100                                                  4.9                 4.3                                                                                2             2
  CKD                                                                                                                                                                                                                                                                                                                                                                                                                                                                           17.6                21.2                                                                                             
  HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.5                 0.3                                                                                              
  Sickle cell disease                                                                                                                                                                                                                                                                                                                                                                                                                                                           0                   0                                                                                                
  Cirrhosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                     9.7                 8.1                                                                                              

                        Abramson et al[14](#jah33503-bib-0014){ref-type="ref"}   Kjaergaard et al[15](#jah33503-bib-0015){ref-type="ref"}   Shalaby et al[16](#jah33503-bib-0016){ref-type="ref"}   Lam et al[17](#jah33503-bib-0017){ref-type="ref"}   Damy et al[18](#jah33503-bib-0018){ref-type="ref"}   Cabrita et al[19](#jah33503-bib-0019){ref-type="ref"}   Choudhary et al[20](#jah33503-bib-0020){ref-type="ref"}                                                 
  --------------------- -------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------- -- ------- ------ ------- ------- ----------- -----------
  Age, y                66.7                                                                                                                72 (65--81)                                             77 (68--81)                                         65±12                                                65±12                                                                                                                73±10   77±9   41±12   46±13   53.1±12.2   58.9±11.6
  Female                15                                                                                                                  36                                                      41                                                  6                                                    16                                                                                                                   36      55                     35.6        32.3
  Race (nonwhite)                                                                                                                                                                                                                                       4                                                    6                                                                                                                                                   100         100
  BMI, kg/m^2^                                                                                                                              26 (23--29)                                             26 (21--28)                                                                                                                                                                                                                   27±5    26±6   25±5    24±6    30.5±6.6    31.8±6.9
  Hypertension                                                                                                                              18                                                      30                                                  71                                                   60                                                                                                                   42.9    50                     52.7        65.6
  DM                                                                                                                                        10                                                      12                                                  47                                                   39                                                                                                                   9.9     16                     20.2        24.9
  Smoking                                                                                                                                   29                                                      29                                                  22                                                   18                                                                                                                   15.6    12                     29.3        34.4
  Obesity                                                                                                                                                                                                                                                                                                                                                                                                                                                        46.1        54.2
  CAD                                                                                                                                       41                                                      43                                                                                                                                                                                                                                                           6.1         9
  Atrial fibrillation                                                                                                                                                                                                                                   34                                                   49                                                                                                                   44.5    55                                 
  COPD                                                                                                                                      18                                                      24                                                  34                                                   27                                                                                                                   43      50                                 
  ILD                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  OSA                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Anemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Heart failure                                                                                                                             76                                                      68                                                                                                                                                                                                                                                           1.4         3.1
  CTD                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  CKD                                                                                                                                       5                                                       9                                                                                                                                                                                                                                                                        
  HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Sickle cell disease                                                                                                                                                                                                                                                                                                                                                                                                                            100     100                 
  Cirrhosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

Continuous variables are presented as mean±SD or median (interquartile range), and categorical variables are presented as percentages. Empty cells indicate data not available. BMI indicates body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; CTD, connective tissue disease; DM, diabetes mellitus; ILD, interstitial lung disease; OSA, obstructive sleep apnea; PH, pulmonary hypertension; Ref., referent group.

Compared with the referent group, mild PH was associated with significantly increased risk of mortality (random‐effects model: RR, 1.52; 95% CI, 1.32--1.74; *P*\<0.001; I^2^=47%; fixed‐effect model: RR, 1.34; 95% CI, 1.27--1.43; *P*\<0.001; I^2^=47%) (Figures [2](#jah33503-fig-0002){ref-type="fig"} and [3](#jah33503-fig-0003){ref-type="fig"}). Secondary analysis using risk‐adjusted time‐to‐event estimates showed results consistent with the direction of primary finding (random‐effects model: HR, 1.19; 95% CI, 1.09--1.31; *P*\<0.001; I^2^=42%; fixed‐effect model: HR, 1.17; 95% CI, 1.11--1.23; *P*\<0.001; I^2^=42%) (Figures [4](#jah33503-fig-0004){ref-type="fig"} and [5](#jah33503-fig-0005){ref-type="fig"}). The findings were consistent between RHC and echocardiography studies (*P* ~interaction~\>0.05). The results were unchanged in a sensitivity analysis, excluding 2 studies that accounted for \>70% of the patients (RR, 1.64; 95% CI, 1.36--1.97; *P*\<0.001; I^2^=47%; and HR, 1.22; 95% CI, 1.07--1.39; *P*=0.004; I^2^=45%).[3](#jah33503-bib-0003){ref-type="ref"}, [20](#jah33503-bib-0020){ref-type="ref"}

![Association between mild pulmonary hypertension (PH) and mortality (random‐effects model). Studies included in this analysis are Valerio et al,[10](#jah33503-bib-0010){ref-type="ref"} Heresi et al,[11](#jah33503-bib-0011){ref-type="ref"} Kovacs et al,[5](#jah33503-bib-0005){ref-type="ref"} Suzuki et al,[12](#jah33503-bib-0012){ref-type="ref"} Maron et al,[3](#jah33503-bib-0003){ref-type="ref"} Takahashi et al,[13](#jah33503-bib-0013){ref-type="ref"} Douschan et al,[4](#jah33503-bib-0004){ref-type="ref"} Assad et al,[2](#jah33503-bib-0002){ref-type="ref"} Abramson et al,[14](#jah33503-bib-0014){ref-type="ref"} Kjaergaard et al,[15](#jah33503-bib-0015){ref-type="ref"} Shalaby et al,[16](#jah33503-bib-0016){ref-type="ref"} Lam et al,[17](#jah33503-bib-0017){ref-type="ref"} Damy et al,[18](#jah33503-bib-0018){ref-type="ref"} Cabrita et al,[19](#jah33503-bib-0019){ref-type="ref"} and Choudhary et al.[20](#jah33503-bib-0020){ref-type="ref"} CI indicates confidence interval; M‐H, Mantel‐Haenszel; RHC, right heart catheterization.](JAH3-7-e009729-g002){#jah33503-fig-0002}

![Association between mild pulmonary hypertension (PH) and mortality (fixed‐effect model). Studies included in this analysis are Valerio et al,[10](#jah33503-bib-0010){ref-type="ref"} Heresi et al,[11](#jah33503-bib-0011){ref-type="ref"} Kovacs et al,[5](#jah33503-bib-0005){ref-type="ref"} Suzuki et al,[12](#jah33503-bib-0012){ref-type="ref"} Maron et al,[3](#jah33503-bib-0003){ref-type="ref"} Takahashi et al,[13](#jah33503-bib-0013){ref-type="ref"} Douschan et al,[4](#jah33503-bib-0004){ref-type="ref"} Assad et al,[2](#jah33503-bib-0002){ref-type="ref"} Abramson et al,[14](#jah33503-bib-0014){ref-type="ref"} Kjaergaard et al,[15](#jah33503-bib-0015){ref-type="ref"} Shalaby et al,[16](#jah33503-bib-0016){ref-type="ref"} Lam et al,[17](#jah33503-bib-0017){ref-type="ref"} Damy et al,[18](#jah33503-bib-0018){ref-type="ref"} Cabrita et al,[19](#jah33503-bib-0019){ref-type="ref"} and Choudhary et al.[20](#jah33503-bib-0020){ref-type="ref"} CI indicates confidence interval; M‐H, Mantel‐Haenszel; RHC, right heart catheterization.](JAH3-7-e009729-g003){#jah33503-fig-0003}

![Pooled hazard ratio for mortality using risk‐adjusted time‐to‐event estimates (random‐effects model). Studies included in this analysis are Heresi et al,[11](#jah33503-bib-0011){ref-type="ref"} Suzuki et al,[12](#jah33503-bib-0012){ref-type="ref"} Maron et al,[3](#jah33503-bib-0003){ref-type="ref"} Takahashi et al,[13](#jah33503-bib-0013){ref-type="ref"} Assad et al,[2](#jah33503-bib-0002){ref-type="ref"} Shalaby et al,[16](#jah33503-bib-0016){ref-type="ref"} Cabrita et al,[19](#jah33503-bib-0019){ref-type="ref"} and Choudhary et al.[20](#jah33503-bib-0020){ref-type="ref"} CI indicates confidence interval; PH, pulmonary hypertension; IV, Inverse Variance; RHC, right heart catheterization.](JAH3-7-e009729-g004){#jah33503-fig-0004}

![Pooled hazard ratio for mortality using risk‐adjusted time‐to‐event estimates (fixed‐effect model). Studies included in this analysis are Heresi et al,[11](#jah33503-bib-0011){ref-type="ref"} Suzuki et al,[12](#jah33503-bib-0012){ref-type="ref"} Maron et al,[3](#jah33503-bib-0003){ref-type="ref"} Takahashi et al,[13](#jah33503-bib-0013){ref-type="ref"} Assad et al,[2](#jah33503-bib-0002){ref-type="ref"} Shalaby et al,[16](#jah33503-bib-0016){ref-type="ref"} Cabrita et al,[19](#jah33503-bib-0019){ref-type="ref"} and Choudhary et al.[20](#jah33503-bib-0020){ref-type="ref"} CI indicates confidence interval; PH, pulmonary hypertension; IV, Inverse Variance; RHC, right heart catheterization.](JAH3-7-e009729-g005){#jah33503-fig-0005}

There was evidence of publication bias on the basis of asymmetry in the funnel plot as well as results of the Egger\'s regression test and the Begg‐Mazumdar rank correlation test (Figure [6](#jah33503-fig-0006){ref-type="fig"}). However, the presence of publication bias did not influence the risk estimate and overall result (Duval and Tweedie\'s Trim and Fill adjusted RR, 1.34; 95% CI, 1.15--1.56) (Figure [7](#jah33503-fig-0007){ref-type="fig"}). Similarly, cumulative meta‐analysis demonstrated that the RR had stabilized with the inclusion of the larger studies and did not shift significantly with the addition of smaller studies, suggesting that the inclusion of smaller studies did not introduce bias (Figure [8](#jah33503-fig-0008){ref-type="fig"}).

![Publication bias assessment. Bias indicators: Begg‐Mazumdar: Kendall\'s τ=0.32381, *P* (1 tailed)=0.046, *P* (2 tailed)=0.092; Egger: intercept=1.31 (95% confidence interval, 0.62--2.01), *P* (1 tailed) \<0.001, *P* (2 tailed)=0.001. MH indicates Mantel‐Haenszel.](JAH3-7-e009729-g006){#jah33503-fig-0006}

![Duval and Tweedie\'s Trim and Fill. The Trim and Fill adjusted risk ratio was 1.34 (95% confidence interval, 1.15--1.56). MH indicates Mantel‐Haenszel.](JAH3-7-e009729-g007){#jah33503-fig-0007}

![Cumulative meta‐analysis (largest to smallest size study). Studies included in this analysis are Valerio et al,[10](#jah33503-bib-0010){ref-type="ref"} Heresi et al,[11](#jah33503-bib-0011){ref-type="ref"} Kovacs et al,[5](#jah33503-bib-0005){ref-type="ref"} Suzuki et al,[12](#jah33503-bib-0012){ref-type="ref"} Maron et al,[3](#jah33503-bib-0003){ref-type="ref"} Takahashi et al,[13](#jah33503-bib-0013){ref-type="ref"} Douschan et al,[4](#jah33503-bib-0004){ref-type="ref"} Assad et al,[2](#jah33503-bib-0002){ref-type="ref"} Abramson et al,[14](#jah33503-bib-0014){ref-type="ref"} Kjaergaard et al,[15](#jah33503-bib-0015){ref-type="ref"} Shalaby et al,[16](#jah33503-bib-0016){ref-type="ref"} Lam et al,[17](#jah33503-bib-0017){ref-type="ref"} Damy et al,[18](#jah33503-bib-0018){ref-type="ref"} Cabrita et al,[19](#jah33503-bib-0019){ref-type="ref"} and Choudhary et al.[20](#jah33503-bib-0020){ref-type="ref"} CI indicates confidence interval; MH, Mantel‐Haenszel; PH, pulmonary hypertension.](JAH3-7-e009729-g008){#jah33503-fig-0008}

Discussion {#jah33503-sec-0017}
==========

Data from this study address controversy on the mPAP level required to capture clinical risk in patients referred for RHC or echocardiography using a meta‐analysis, which is the optimal research tool for determining aggregate risk across study populations.[26](#jah33503-bib-0026){ref-type="ref"} We report that mildly elevated PA pressures, estimated by either echocardiography or invasive catheterization, are associated with 19% increased risk of mortality over 5 years. Despite analyzing both community‐based and referral populations with varying underlying comorbidities, there was only mild statistical heterogeneity of risk across the included studies. This suggests a truly generalizable association between mild PH and mortality. These data support the ongoing efforts to identify optimal cutoffs for hemodynamic parameters in PH, including pulmonary arterial hypertension, to identify at‐risk populations earlier.[27](#jah33503-bib-0027){ref-type="ref"}

A notable finding of this study is the consistent association between mild PH and increased mortality when PA pressure was measured by either RHC or echocardiography. Although RHC is the only test available to diagnose PH, echocardiography is the preferred screening test for at‐risk patients.[6](#jah33503-bib-0006){ref-type="ref"} Current guidelines recommend further evaluation of patients for PH if the tricuspid regurgitation velocity is \>2.9 m/s (corresponding to PASP \>≈40 mm Hg).[6](#jah33503-bib-0006){ref-type="ref"} However, our findings demonstrate that PA pressure assessed by echocardiography, at levels considered currently to be below the range of clinical significance (tricuspid regurgitation velocity ≈\>2.5 m/s, PASP \>35 mm Hg) across both community‐based and referral populations, is, in fact, a valid predictor of mortality. Thus, our data suggest that when PA pressure can be measured by echocardiography, this is an effective screening tool for detecting patients at risk for mild PH who may benefit from further evaluation, close follow‐up, and risk reduction interventions.[17](#jah33503-bib-0017){ref-type="ref"}, [20](#jah33503-bib-0020){ref-type="ref"} Nonetheless, a recent study in patients with PH (mPAP \>25 mm Hg) demonstrated modest correlation and poor agreement between echocardiography‐derived and RHC‐measured PASP and mPAP.[28](#jah33503-bib-0028){ref-type="ref"} Fisher et al[29](#jah33503-bib-0029){ref-type="ref"} showed that approximately half of the cases of PASP overestimation are related solely to right atrial pressure overestimation by echocardiography. Thus, although we used an assumed right atrial pressure of 5 mm Hg for calculating PASP in echocardiography studies that reported only tricuspid regurgitation velocity or gradient, concern for misclassification remains when relying on echocardiography alone for the diagnosis of PH (or mild PH). Furthermore, the effect sizes of mild PH, as estimated by RHC and echocardiography on mortality, although different, are not directly comparable to suggest different clinical recommendations for patients with mild PH diagnosed via these 2 modalities.

Our meta‐analysis, together with findings from the individual studies analyzed, provides comprehensive evidence in support of defining PH in contemporary and clinically relevant terms. Specifically, these data affirm the reproducibility across selected and unselected populations for mPAP \>19 mm Hg as an appropriate and clinically accessible level distinguishing patients with PH from patients without PH. Acknowledging this would identify previously undiagnosed patients with PH and provide a framework in clinical practice by which to initiate careful monitoring and efforts to modify risk factors.[30](#jah33503-bib-0030){ref-type="ref"} These patients should also be considered for enrollment in ongoing and future PH clinical trials investigating pharmacological and nonpharmacological (eg, exercise program and weight loss) interventions to attenuate risk and improve outcomes in this population. Indeed, randomized controlled trials examining the efficacy and safety of established pulmonary artery hypertension therapies in patients with mild mPAP are already underway.[31](#jah33503-bib-0031){ref-type="ref"}

Limitations {#jah33503-sec-0018}
-----------

First, this is a meta‐analysis of nonrandomized studies and has all limitations of observational data, including selection bias and unmeasured confounding variables. Second, restricted by the nature and characteristics of this meta‐analysis, we did not have access to patient‐level data. Therefore, we are unable to characterize covariates that modulate risk within the mild PH group, such as elevated pulmonary vascular resistance. This is a particularly important limitation, because the addition of pulmonary vascular resistance to analysis of cardiopulmonary hemodynamic data is needed to exclude mildly increased PA pressure that is physiologic in the setting of increased cardiac output or cor pulmonale from a diagnosis of mild PH. Similarly, although we performed analysis using adjusted HRs, the precise impact of comorbidities cannot be readily assessed across studies in the absence of patient‐level data. Third, the possibility that differences in cardiopulmonary comorbidities and not PA pressure were responsible for differences in clinical outcome in this group cannot be excluded. However, pooled HRs derived from risk‐adjusted time‐to‐event estimates demonstrated a 19% increased risk of mortality in patients with mild PH compared with the referent group. Fourth, the association of mild PH and mortality in the subgroups of patients with cardiac, pulmonary, hematologic, or connective tissue disease could not be determined because of unavailability of mortality data in these different subgroups. Last, the mortality estimates are based on an mPAP cutoff of ≈19 to 20 mm Hg that was selected from prior published data, although a lower cutoff may yield slightly different results.

Conclusion {#jah33503-sec-0019}
==========

In a meta‐analysis of 15 nonrandomized studies, mild PH was associated with an increased risk of all‐cause mortality compared with the referent group. This finding was consistent in the subgroups of RHC and echocardiography studies. These data add to the growing body of literature on the hemodynamic range and prognostic significance of mild PH. Overall, our data affirm efforts to update the current PH definition and provide definitive data in support of future clinical trials to improve outcome in this vulnerable patient subgroup.
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